Financial Daily from THE HINDU group of publications
Thursday, Jul 04, 2002

Port Info

Group Sites

Corporate - Outlook

Sanofi-Synthelabo eyes 20% growth in topline

Our Bureau

MUMBAI, July 3

SANOFI-SYNTHELABO (India) Ltd expects to witness 18-20 per cent growth in topline for the financial year 2002-03.

Speaking to newspersons here on the occasion of the parent company Sanofi-Synthelabo group listing on the New York Stock Exchange, Dr Shailesh Ayyangar, Managing Director, Sanofi-Synthelabo India Ltd, said that the company expected a turnover of Rs 60 crore, a 18-20 per cent growth over last year's sales.

On the group's plans for its wholly-owned Indian subsidiary, Dr Ayyangar said: "During the course of next few years, Sanofi-Synthelabo India will be actively pursuing the path of augmenting and diversifying its product portfolio through launching of new products.''

Sanofi-Synthelabo (India) Ltd would be launching 8-10 products in the next two to three years in India.

"We would be introducing these products in a phased manner. This would be achieved through a careful selection of products to be launched from the strong stable of products from our parent company, new molecules being considered for registration in India from the company's research and development pipeline and through targeted acquisitions,'' Dr Ayyangar said.

The company has a presence in segments such as central nervous system, cardiology, epilepsy and thrombosis. According to Dr Ayyangar, the company plans to enter many more segments, particularly neuropsychiatry, in the ensuing years in the Indian pharmaceutical market.

The company will introduce one product by the end of 2002 or early 2003, Dr Ayyangar said. The company has about 175 medical representatives and plans to expand the field force when required, he added.

On being queried about alliances with Indian companies, Dr Ayyangar said that the company is open to alliances with Indian companies. "We have been approached by several blue-chip Indian companies for alliances,'' he said.

Send this article to Friends by E-Mail

Stories in this Section
German pharma co plans research in India on AIDS

Ranbaxy gets US FDA nod for Lisinopril
Hepatitis B vaccine prices slashed
SEBI panel findings on buyback by month-end
ICAI renames auditing practices panel — Regulatory bodies, public to have a say henceforth
Jargons ajar
HDFC subscribes to 6.9 pc preference shares of RIL
Sasken converts Japanese arm into branch office
Sesa Goa seeks to dispose of Sirsaim unit
ACC to sell stake in Intl Ferrites in Rs 40-cr deal
Idea Cellular-BPL merger in a limbo
IOC denies imposing fresh riders on HPL
Alfa Laval India to be hub for global projects business
Singareni Collieries hopes to wipe out losses this fiscal
Sanofi-Synthelabo eyes 20% growth in topline
M.K. Sinha takes over at NCL
Alstom board reconstituted

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | Home |

Copyright 2002, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line